156573-32-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloro-4-iodobenzoate is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Methyl 2-chloro-4-iodobenzoate is used as an intermediate in the production of agrochemicals. Its versatility enables the creation of new compounds with potential applications in agriculture, such as pesticides and herbicides.
Used in Organic Synthesis:
Methyl 2-chloro-4-iodobenzoate is used as a versatile intermediate in organic synthesis. Its unique structure allows for the development of new compounds with various applications in different industries.
Used in Fine Chemicals Production:
Methyl 2-chloro-4-iodobenzoate is used in the production of fine chemicals. Its unique properties make it a valuable component in the synthesis of specialty chemicals for various applications.

InChI:InChI=1/C8H6ClIO2/c1-12-8(11)6-3-2-5(10)4-7(6)9/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 145343-76-6 2-chloro-4-iodobenzoic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 610-96-8 methyl chlorobenzoate 
• 1379464-66-0 2-chloro-N-(2-methoxyphenyl)-4-((4-nitrophenyl)thio)benzamide 
• 1379464-65-9 2-chloro-4-((4-nitrophenyl)thio)benzoic acid 
• 1379464-64-8 methyl 2-chloro-4-((4-nitrophenyl)thio)benzoate 

Relevant academic research and scientific papers

Radioiodinated N-(2-aminoethyl)-2-chloro-4-iodobenzamide: A new ligand for monoamine oxidase B studies with single photon emission computed tomography

In developing monoamine oxidase (MAO)-B specific radioligands, N-(2-aminoethyl)-2-chloro-4-[125I]iodobenzamide ([125I]FIBA) was conveniently synthesized from its tributylstannyl precursor by an iododestannylation reaction using sodiu

Photoinduced Cross-Coupling of Aryl Iodides with Alkenes

A protocol for photoinduced cross-coupling of aryl iodides having polar π-functional groups or elongated π-conjugation with alkenes has been developed. The radical cascade mechanism involving generation of aryl radicals via C-I bond homolysis of photoexcited aryl iodides and their subsequent addition to alkenes is proposed. The method enables iodide-selective cross-coupling over other halogen leaving groups with functional group compatibility on both arene and alkene motifs.

INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically accept

RXR-agonist polycyclic aromatic compounds, pharmaceutical/cosmetic compositions comprising said compound and uses thereof

Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds having the structural formula (I): wherein Ar is a radical having one of the formulae (a)-(e): which are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders are provided. In particular, based on their RXR-agonist activity, these compounds may be used to treat noninsulin-dependent diabetes mellitus (NIDDM) and obesity.

Polyaromatic propynyl compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polyaromatic propynyl compounds have the structural formula (1): STR1 in which X is one of the radicals: STR2 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.

Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof

Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds have the structural formula (I): STR1 wherein Ar is a radical having one of the formulae (a)-(i): STR2 and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.